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In recent years, pramipexole and other direct-acting dopamine agonist 
medications have been implicated in the development of impulsive behaviors such as 
pathological gambling in patients with Parkinson’s disease. Despite the significance 
of these clinical findings, experimental evaluations of pramipexole’s effects on 
gambling are lacking. To this end, the present study used an animal model 
approximating some aspects of human gambling to examine within-subject effects of 
acute pramipexole on rats’ preferences for gambling-like sources of reinforcement. 
Pramipexole modestly but significantly increased preferences for gambling-like 
reinforcement when compared to saline. Pramipexole also increased response 
latencies, but did not affect probabilities of response perseveration. The findings of 
the present study are consistent with clinical reports linking pramipexole to gambling. 
Results are discussed in the context of neurobehavioral evidence suggesting a critical 
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Pramipexole is a dopamine (DA) D2/D3 receptor agonist commonly prescribed 
as part of dopamine replacement therapy for Parkinson’s disease (PD). Pramipexole 
has high selective affinity for the D3 receptor subtype (Bennet & Piercey, 1999) 
which is predominantly expressed in the limbic areas of the brain (Sokoloff et al., 
1990). Limbic areas are thought to mediate aspects of addictions to drugs and 
gambling (Lader, 2008). Several clinical reports indicate that when some patients 
with PD are treated with D2/D3 agonists, like pramipexole, they develop impulse 
control disorders (ICDs) such as pathological gambling (Dodd et al., 2005; Driver-
Dunckley, Samanta, & Stacy, 2003; Grosset et al., 2006; Molina et al., 2000), 
compulsive shopping (Giladi et al., 2007), hypersexuality (Giovannoni et al., 2000; 
Klos et al., 2005; McKeon et al., 2007; Munhoz, Fabiani, Becker, & Teive, 2009), 
and compulsive eating (Nirenberg & Waters, 2006). The causal role of these agonist 
medications in the development of impulsive behaviors is suggested by the absence 
(or socially acceptable frequency) of ICDs prior to drug therapy and the subsequent 
resolution of the problematic behavior once drug use is discontinued (e.g., 
Mamikonyan et al., 2008). 
Of the aforementioned ICDs, incidence of pathologic gambling in PD patients 
prescribed D2/D3 agonists has been a subject of particular interest (e.g., Imamura et 
al., 2008; Ondo & Lai, 2008). For example, the Food and Drug Administration’s 2005 
Adverse Event Reporting System Database listed 67 pramipexole-associated 
gambling incidents; 58% of the total reported cases of side effects of this drug 
(Szarfman, Doraiswamy, Tonning, & Levine, 2006). Prevalence estimates of 
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pathological gambling among PD patients treated with D2/D3 agonists range from 0.5-
7.2%, higher than a recent U.S. population estimate of 0.4% (Petry, Stinson, & Grant, 
2005). Even so, some researchers have speculated that the effects of D2/D3 agonists 
on PD patients’ gambling have been underestimated because of inadequate screening 
procedures, reluctance to admit a problem, lack of context to express gambling 
behavior, or the exclusion of patients whose problem gambling does not meet 
pathologic levels (e.g., Potenza, Voon, & Weintraub, 2007).   
To our knowledge, only two laboratory experiments have examined the 
relation between pramipexole and gambling-related activities. Riba, Krämer, 
Heldmann, Richter, and Münte (2008) presented healthy human participants with a 
task in which choosing one option resulted in an equally probable (i.e., 50%) win or 
loss of 25 cents or a “boost” win (i.e., 50 cents) that occurred unpredictably on half of 
the win trials. Choosing the other option had similar outcomes, but with 5 cents as the 
amount won or lost (10 cents for a “boost” win). In a comparison of the within-
subject effects of 0.5 mg pramipexole vs. placebo in this lottery-style task, Riba and 
colleagues reported that pramipexole significantly increased persistence for the 25 
cent option immediately following a “boost” win at this alternative, despite the fact 
that wins and losses were equally likely throughout the session (no other comparisons 
were significant). Pre-session pramipexole also produced hypoactivation of reward-
related brain regions (e.g., ventral striatum, cingulate gyrus) which Riba et al. 
speculated may be related to the blunted responsiveness to risk. 
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The other experimental examination of the effects of pramipexole on behavior 
related to addictions was conducted by Hamidovic, Kang, and de Wit (2008) who 
reported no significant effects of 0.25 or 0.5 mg pramipexole on human impulsivity in 
delay and probability discounting tasks. In these tasks, participants were asked to 
choose between a smaller monetary amount available immediately (or with 100% 
certainty) and a larger amount whose receipt was delayed in time (or less than 100% 
certainty). Depending on a participant’s choices, the smaller monetary amount was 
adjusted until a point of subjective indifference between the small and large amounts 
was obtained. The task was then repeated across a range of delay and probability 
values for the larger amount in order to generate a curve whose steepness is a 
common metric of impulsivity. Although no significant differences in discounting 
were found between placebo and drug sessions, their sample of 8 participants 
demonstrated a dose-dependent trend toward more impulsive choice in the delay 
discounting task. Consistent with this trend, an experiment recently conducted in our 
laboratory reveals a significant increase in impulsive choice in rats given pre-session 
injections of pramipexole at doses of 0.1, 0.18, & 0.3 mg/kg (Madden, Johnson, 
Brewer, Pinkston, Fowler, & Woods, in preparation). It should be noted, however, 
that this effect was not reproduced in two subsequent experiments using a different 
procedure (that developed by Evenden & Ryan, 1996). 
These laboratory findings, when combined with the clinical-reports literature 
on gambling in PD patients, suggest D2/D3 agonist medications (like pramipexole) 
may increase ICDs such as pathological gambling. Additional experimental data is 
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needed to thoroughly address this hypothesis. Because human research necessarily 
involves uncontrollable behavioral histories and ethical issues (e.g., participants 
cannot gamble with their own money), nonhuman assessments of pramipexole’s 
effects on impulsivity may provide insights into this phenomenon. 
The present study was designed to explore the effects of pramipexole on 
gambling-like behavior in rats. We selected a nonhuman laboratory preparation to 
control subjects’ learning history and to make it possible to schedule important 
reinforcing consequences in a manner similar to the way in which wins occur in 
human gambling (e.g., Kendall, 1987; 1989). For these purposes, a choice procedure 
was used to determine if pramipexole increases preference for “gambling” over a 
predictable source of reinforcement.  
Rats completed 4-hour sessions in which they earned their entire ration of 
food for the day by responding on levers in an operant chamber (i.e., a closed 
economy). Within each session, rats had a fixed budget (i.e., a finite number of lever-
press responses) to “spend” on food each day. Once the rat’s budget had been 
exhausted, the session ended and food was unavailable until the next day’s session. 
Because human pathological gambling frequently results in a net loss of income, 
conditions were arranged such that food earned from the “gambling” alternative was 
more expensive than that obtained on a separate lever where food was arranged more 
predictably. Thus, given the “budgetary limitations” in this preparation, choosing the 
gambling-like alternative negatively affected food intake (i.e., income) and arranged 





Seven experimentally naïve male Wistar rats obtained from Charles River 
(Wilmington, MA) served as subjects. Rats were housed individually with the 
exception of two that were housed together due to space limitations. A continuous 
12/12 light/dark cycle was arranged in the colony room and water was available ad 
libidum in all home cages and within the experimental chambers. Nutritional grain-
based rat pellets (45 mg; Bio-Serv, Frenchtown, NJ) earned during experimental 
sessions were the only available source of food (i.e., no supplemental feedings were 
provided for the duration of the experiment) as is characteristic of a closed economy. 
Weights were recorded daily to ensure subjects maintained at least 85% ad libidum 
weight throughout the experiment. All animal use was in accordance with the 
Institutional Animal Care and Use Committee (IACUC) of the University of Kansas. 
Apparatus 
 Sessions took place within standard operant chambers (24.1 cm x 30.5 cm x 
21.0 cm; Med Associates, Inc., St. Albans, VT). Centered on the front wall of each 
chamber and positioned 1 cm above the floor grid was a pellet receptacle (3 cm x 4 
cm) into which a pellet dispenser (Coulbourn Instruments, Allentown, PA) could 
deliver 45-mg food pellets. Above the receptacle (10 cm) was a non-retractable lever 
with retractable levers to the left and right (spaced 11 cm apart). A 28-volt DC 
shielded stimulus lamp was positioned 6 cm above each lever. A house light was 
centered 19 cm above the floor on the rear wall. Each chamber was equipped with a 
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white noise speaker and was situated within a sound-attenuating box (Med 
Associates, Inc.). All experimental events were programmed using MED-PC software 
and were executed via a PC in an adjacent room. 
Procedure 
 Prior to the first experimental session, reliable responding on all three levers 
was established using an autoshaping procedure. Following autoshaping, rats 
completed sessions in which they were able to choose between obtaining food from a 
predictable food source (fixed number of lever presses required to obtain food) or 
from a “gambling” food source (unpredictable number of lever presses required per 
food reinforcer). Each experimental session began with a series of four 21-trial 
blocks. The first 16 trials in each block were forced-choice trials designed to expose 
the rat to the contingencies of reinforcement arranged on the gambling and non-
gambling alternatives before free choices would be made. The first 8 forced-choice 
trials were completed on one lever (randomly selected) and the remaining 8 trials 
were completed on the other lever. These forced-choice trials permitted ample 
exposure to the four possible response requirements comprising the gambling 
alternative (discussed below). The lever to which the gambling alternative was 
assigned was counterbalanced across subjects.  
On forced-choice trials, a single response on the center lever extinguished the 
lamp above the center lever and lit the lamp above one of the two side levers which 
was inserted into the chamber. If the gambling lever was inserted, the rat was required 
to complete a variable-ratio (VR) schedule requirement on that lever to obtain three 
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food pellets. The VR requirement was completed when either 1, 33, 67, or 99 
responses were emitted. Between trials, the VR response requirement was randomly 
determined with replacement. In this way, VR response requirements were 
unpredictable and “gambling-like,” approximating the unpredictability of the number 
of wagers that must be placed before a win in the human gambling milieu.  
If the non-gambling lever was inserted on a forced-choice trial, the rat was 
required to complete a fixed-ratio (FR) schedule requirement to earn three food 
pellets. Unlike the VR response requirements, the number of responses required per 
food pellet was the same every time pellets were obtained. In this way, the FR 
response requirement was designed to simulate non-gambling sources of human 
income (e.g., predictable income earned upon completion of a job).  
To enhance discrimination between the different contingencies arranged on 
the two levers, for 4 of the rats the stimulus lamp above the gambling alternative 
flashed at a 0.5-second frequency, while the stimulus lamp for the non-gambling 
alternative remained constantly illuminated. For the other 3 rats, this stimulus pairing 
was reversed. Once the response requirement was completed, the stimulus lamp and 
house light were immediately extinguished, the side lever retracted, and three food 
pellets were delivered, each of which was accompanied by a 0.5-second flash of light 
from within the pellet receptacle. The next trial was initiated immediately after the 
last pellet was delivered. 
The five remaining trials within each of the four 21-trial blocks were free-
choice trials. On free-choice trials after the rat pressed the center lever, the stimulus 
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lamps above both side levers were lit (one flashing). To allow adequate exposure to 
these stimuli, the rat was then required to emit four additional responses on the center 
lever before the center lamp was extinguished and both side levers were inserted into 
the chamber. On free-choice trials a single response on a side lever retracted the other 
lever and extinguished its stimulus lamp for the remainder of the trial. Once the 
scheduled contingency on the operative lever was satisfied, the stimulus lamp and 
house light were extinguished, the lever was retracted, and three food pellets were 
delivered as in forced-choice trials. The next trial was initiated immediately after the 
last pellet was delivered. After four of these 21-trial blocks (84 trials), the remainder 
of the session was composed of free-choice trials. Sessions continued until the rat had 
expended its response budget (see below) or 4 hours elapsed, whichever came first.   
Response budget. Responses allocated to either side lever on the free-choice 
trials were subtracted from a daily fixed response budget. Responses emitted on 
forced-choice trials were not counted against the response budget. When the rat 
exhausted its response budget, the session ended – all lights in the chamber were 
extinguished and side levers were retracted.  
The daily response budget was arranged such that exclusive preference for the 
FR alternative always resulted in the maximum amount of food obtainable (121 
reinforcer events) and any free choices allocated to the VR alternative resulted in 
relatively less income. This was because the average VR value was always higher 
than that arranged on the FR lever. Thus, allocating responses to the VR alternative 
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reduced within-session food earnings when compared to what could have been 
obtained had the FR alternative been exclusively selected. 
Low-gambling baseline. Rats were randomly assigned to begin the study in 
conditions arranged to produce either low or high preference for the gambling (VR) 
alternative. Low preference for gambling was defined as 20% or fewer free-choices 
on the gambling lever. Pilot research indicated an FR requirement of 5 responses (FR-
5) produced low preference for gambling, so FR-5 was initially programmed. If a 
rat’s percent choice for the gambling alternative exceeded 20% for two consecutive 
sessions, the FR requirement was decreased until percent VR choice was below the 
20% criterion; these adjustments occurred in 3 of 7 rats (see Table 1). One rat (Red 2) 
chose the VR alternative on more than 20% of the free choice trials even at FR-2. For 
this rat, FR-2 served as the terminal requirement on the non-gambling alternative. 
After ten consecutive sessions in which VR choice was less than 20%, and the 
FR value was not adjusted across those sessions, the pre-session drug-administration 
regimen was initiated (see below). At the conclusion of this condition, rats that 
completed the low-gambling baseline first completed the high-gambling baseline 
next. Subjects that completed the high-gambling baseline prior to the low-gambling 
baseline (opposite order) finished the study upon completing this condition. 
High-gambling baseline. In addition to the low-gambling baseline, a baseline 
of high-gambling preference was examined to address the possibility that increases in 
percent VR choice in the low-gambling baseline might be explained by non-specific 
drug effects (e.g., compromised discrimination). Decreases in percent VR choice in 
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the high-gambling baseline, symmetrical to those seen in the low-gambling baseline, 
would suggest these non-specific effects. 
To produce high-gambling preference, pilot data suggested that an FR-40 
would yield >80% choice of the VR alternative on free-choice trials. In all cases, rats 
met this high-gambling criterion at FR-40. Ten consecutive sessions within this 
range, with no adjustments to the FR value, satisfied the stability criterion and 
initiated the pre-session drug-administration regimen. 
At the conclusion of this condition, rats completing this high-gambling 
baseline first then completed the low-gambling baseline. Rats that completed the low-
gambling baseline prior to the high-gambling baseline (opposite order) finished the 
study upon completing this condition. 
Drug administration. Pramipexole (N'-propyl-4,5,6,7-
tetrahydrobenzothiazole-2,6-diamine dihydrochloride) was synthesized and provided 
by Drs. Shaomeng Wang and Jianyong Chen (University of Michigan, Ann Arbor, 
MI). Pramipexole was dissolved in physiological saline, refrigerated, and protected 
from light. Four doses of pramipexole (0.03, 0.1, 0.18, 0.3) or saline vehicle were 
administered subcutaneously 10 min prior to the session at a volume of 1.0 ml/kg 
(Collins et al., 2005). 
 Once a stable low- or high-gambling baseline was established, an initial saline 
dose was administered. Pramipexole was then administered in a descending dose 
order as previous work in the Fowler lab with dopamine agonists has indicated that 
the effects of smaller doses may change after larger doses are administered, and so 
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beginning the sequence with the larger dose may minimize variability. Each saline or 
drug administration was separated by at least four no-injection sessions (median: 4; 
range: 4-22 days). These sessions continued until choice returned to the baseline 
range for four consecutive sessions. After each dose in the descending series was 
tested, the dosing regimen was repeated two times, each time separated by a saline 
session. Again, after all doses had been administered in either the low- or high-
gambling baseline, the rat completed three series of pre-session pramipexole 
administrations in the remaining baseline condition. 
Data analysis. The primary dependent measure of interest was percent choice 
for the gambling-like, VR alternative. Data from low- and high-gambling baselines 
were analyzed using separate two-way repeated-measures analysis of variance 
(ANOVA; SPSS 16.0, SPSS Inc., Chicago, IL) with “dose” (saline, 0.03, 0.1, 0.18, 
0.3) and “series” (first, second, and third) as within-subject factors. One rat (Blue 4) 
failed to complete any free-choice trials across two sessions at the 0.3 mg/kg dose. 
This single piece of missing data was replaced by the across-subjects mean percent 
VR choice at that dose. A paired-samples t-test was used to test for differences 
between VR values obtained from drug sessions in low- and high-gambling baselines. 
Because of the known motor-impairing effects of pramipexole (Lagos et al., 
1998), median latencies to respond on all three levers (center, FR, and VR) were 
recorded. To facilitate comparison of latencies from low- and high-gambling 
baselines, differences between control (no injection) and drug session latencies were 
computed and subjected to three-way repeated-measures ANOVAs with “dose,” 
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“series,” and “baseline” (low- or high-gambling) as within-subject factors. In the 
cases of median FR and VR latencies, only data from forced-choice trials were used 
in these analyses because subjects occasionally exhibited exclusive choice for a single 
alternative in all free-choice trials during a session. 
Lastly, because recent research detected D2/D3 agonist-related increases in 
perseverative responding (Boulougouris, Castañé, & Robbins, 2009), conditional 
probabilities of same-lever choice in transitions between forced- and free-choice trials 
were calculated and analyzed using three-way ANOVA. On occasions where 
distributions violated assumptions of sphericity and were not amenable to 
transformations, F statistics were compared to critical values calculated using 
Greenhouse-Geisser adjusted degrees of freedom. 
Results  
Results of a paired-samples t-test indicated VR values obtained in the drug 
sessions did not differ significantly across low- and high-gambling baseline 
conditions (t(104) = 1.08, p = .28). 
Figure 1 shows group and individual mean percent VR choice (+ SEM) as a 
function of pramipexole dose (see Table 1 in Appendix A). In the low-gambling 
baseline, represented by the open symbols, pramipexole significantly increased 
percent VR choice relative to saline levels (significant main effect of dose: F(4, 24) = 
6.94, p = .001, ηp2 = .54), but the effect was not dose related (linear contrast: p = 
.063). An effect of dosing series (i.e., first, second, or third exposure to saline and 
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Figure 1. Mean percent VR choice as a function of pramipexole dose in low- (○) and 
high-gambling (●) baselines. “C” and “S” represent control (no injection) and saline, 
respectively. Circles, squares, and triangles represent dosing series 1-3, respectively. 
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This sensitization effect was observed between the first (circles) and second (squares) 
series of doses. 
Also shown in Figure 1 are data from the high-gambling baseline (see Table 2 
in Appendix A). In this baseline (filled symbols), percent VR choice in drug sessions 
was not significantly different from saline sessions (p = .33), and there was no 
significant main effect of series (p = .82). As stated previously, this baseline acted as 
a control condition for the possibility that pramipexole-related increases in the low-
gambling baseline could be alternatively explained by non-specific drug effects such 
as disrupted discrimination between response alternatives. If this were the case, 
percent VR choice in the high-gambling baseline would likely have decreased in a 
manner opposite the increases seen in the low-gambling baseline. This effect is absent 
in Figure 1, suggesting that non-specific effects likely did not account for the 
increases in percent VR choice observed in the low-gambling baseline. 
Figure 2 shows median latencies to respond on the center lever, expressed as a 
difference from control (no injection) center-lever latencies. As is evident in the 
grouped data, latency differences from control tended to increase as a function of 
dose (significant main effect of dose: F(4, 24) = 25.45, p < .001, ηp2 = .81; significant 
linear contrast: p = .02). None of the interactions involving dose were significant (p’s 
≥ .09). Latency differences depended upon the dosing series and baseline condition 
(series x baseline interaction: F(2,12) = 6.99, p = .01, ηp2 = .54). Follow-up ANOVAs 
were conducted for each baseline and revealed that only in the high-gambling 


































S 0.01 0.1 1.0
Blue 4




















Figure 2. Difference between median drug and control center lever latencies as a 
function of pramipexole dose in low- (○) and high-gambling (●) baselines. Circles, 
squares, and triangles represent dosing series 1-3, respectively. Note y-axis scales for 
Blue 4 and Black 4. 
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latency difference (significant series x dose interaction: F(8,48) = 35.3, p < .04, ηp2 = 
.27), suggesting baseline-dependent sensitization to repeated drug exposures. 
Figure 3 shows median latencies to make the first response on the FR lever on 
forced-FR trials, expressed as a difference from control (no injection) FR latencies. 
As in the previous figures, latencies are separated by baseline and dosing series. 
Latencies in the high-gambling baseline were significantly longer than those in the 
low-gambling baseline (main effect of baseline: F(1, 6) = 50.42, p < .01, ηp2 = .83). A 
significant dose x baseline interaction was also detected (F(4, 24) = 3.78, p < .02, ηp2 
= .39). Further investigation of this interaction using a paired samples t-test revealed 
significant differences in latency differences between the two baselines at all active 
doses (all p’s ≤ .001). Latency differences in saline sessions were not different across 
low- and high-gambling baselines (t(20) = .395, p = .7).  
Figure 4 shows differences between median drug and control VR lever 
latencies for both baselines. Median VR latencies were brief compared to latencies on 
the center and FR levers (compare Figs. 3 and 4). Because no main effect was evident 
for series and it did not interact with other variables, data shown in Figure 4 were 
collapsed across this factor. Significant main effects of dose (F(4,80) = 7.8, p < .001, 
ηp2 = .28) and baseline (F(1,20) = 7.8, p = .013, ηp2 = .27) were observed; however, 
there was no significant dose x baseline interaction (p = .11). Post-hoc Bonferonni-
corrected comparisons revealed significantly smaller differences between control and 
drug VR latencies in the high-gambling baseline compared with latencies in the low-




















































































Figure 3. Difference between median drug and control FR lever latencies as a 
function of pramipexole dose in low- (○) and high-gambling (●) baselines. Circles, 
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Figure 4. Difference between median drug and control VR lever latencies as a 
function of pramipexole dose in low- (○) and high-gambling (●) baselines. “C” and 
“S” represent control (no injection) and saline, respectively. Error bars are SEM. 
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To investigate the perseverative effects of pramipexole (e.g., Boulougouris et 
al., 2009), the conditional probability of making the first free-choice on the lever that 
ended the series of forced-choice trials was calculated at each dose. Specifically, 
transitions in which subjects chose the alternative (i.e., during a free-choice trial) that 
had been presented in the immediately preceding forced-choice trial (i.e., staying) 
were scored as positive instances. Choices for the alternative opposite the one forced 
in the immediately preceding trial (i.e., switching) received neutral scores. The sum 
of these instances divided by the total number of forced-free transitions within a 
session (the maximum was 4) permitted a measure of response perseveration. 
 Figure 5 shows mean conditional probabilities of the first free-choice 
occurring for the recently-forced lever in both low- and high-gambling baselines. 
Probabilities were unaffected by baseline condition (p > .8). Significant main effects 
of dose (F(4, 52) = 2.74, p < .04, ηp2 = .17) and of series (F(2, 26) = 5.71, p < .01, ηp2 
= .31) were detected. The only significant differences identified by post-hoc 
Bonferroni-corrected pairwise comparisons were those between the mean conditional 
probabilities at saline and 0.18 mg/kg (p = .03). Interestingly, mean conditional 
probabilities of staying at a recently-forced alternative were highest in saline sessions 
(mean = .57) and lowest in sessions in which 0.18 mg/kg was administered (mean = 
.45), indicating an increased probability of switching to the alternative opposite to the 
one that had been recently forced. Conditional probabilities in sessions in which 
smaller doses were administered were more similar to saline probabilities, suggesting 
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Figure 5. Individual and group conditional probabilities of making the first free-
choice on the lever that ended the series of forced-choice trials in low- (□) and high-
gambling (■) baselines. Error bars are SEM. 
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factor level means for series also indicated a decreasing linear trend in the probability 
of same-lever responding with repeated administrations (p = .02). 
Discussion 
In the present study, an animal model of gambling was used to determine the 
effects of pramipexole, a D2/D3 dopamine agonist, on preference for gambling-like 
sources of reinforcement. Of primary importance is the finding that acute 
administration of pramipexole was observed to modestly increase rats’ preferences 
for food reinforcement obtained from a gambling-like alternative relative to saline 
levels. When pramipexole was administered under baseline conditions of high-
gambling preference, the drug did not significantly affect choice for the gambling-like 
alternative. This pattern of results appears consistent with the clinically documented 
coinciding events of emergent pathological gambling and initiation of pramipexole 
and other dopamine agonist regimens (Crockford et al., 2008). Further, because 
preference was affected solely in the low-gambling baseline, additional explanations 
for the present findings, such as compromised discrimination between the two 
response alternatives, can be tentatively ruled out.  
In contrast, non-specific drug effects were unlikely completely absent in the 
present study. Consistent with previous findings that pramipexole (Lagos et al., 1998) 
and other D3-preferring agonists (Ouagazzal & Creese, 2000) suppress locomotor 
activity, pramipexole increased latencies to initiate new trials (center lever) and to 
begin responding on the FR or VR alternatives (forced-choice only) when compared 
to latencies from control sessions. Although generalizing  across species is difficult, 
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human simple and procedural reaction times also increase as a function of acute 
pramipexole dose (Hamidovic et al., 2008; Pizzagalli et al., 2008), suggesting a 
common effect of D3-preferring medications to decrease motor activity. 
Given recent evidence that quinpirole, a D2/D3 dopamine agonist like 
pramipexole (but with lower relative preference for D3 to D2 receptors), inhibits 
reversal learning (i.e., promotes response perseveration) (Boulougouris et al., 2009), 
we speculated that in drug sessions rats would be more likely to choose an alternative 
in a free-choice trial that had been the forced-choice in the immediately preceding 
trial. This hypothesis was not supported. Indeed, the conditional probability of a 
perseverative free-choice actually decreased during pramipexole sessions when 
compared to saline sessions. 
Together, these findings lend credence to a putative link between pramipexole 
and impulsive behavior identified by the existing clinical literature. More importantly, 
the results of the present study provide a systematic extension of previous 
experimental investigations related to pramipexole and other D2/D3 agonist-induced 
behavioral perturbations in healthy subjects (e.g., Hamidovic et al., 2008; Riba et al., 
2008). Unlike these previous studies, the present experiment and others conducted in 
our laboratory (e.g., Madden et al., in preparation) demonstrate the viability of 
nonhuman models of impulsive decision-making and their ability to characterize 
within-subject drug effects in a population whose historical experiences are well-
described and controlled. Along with these studies, the preliminary interpretations 
that follow take into account current neurobehavioral research regarding the influence 
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of endogenous dopamine and dopaminergic medications on brain activation in areas 
correlated with impulsive or risky decision-making. More specifically, the disruptive 
effects of pramipexole on reward- and punishment-related learning processes and 
their implications for the present findings are discussed. 
Dopaminergic Participation in Dysfunctional Learning 
 Through the use of neuroimaging technologies, researchers have recently 
identified brain regions involved in aspects of reward-related learning. Of note are 
midbrain structures such as the ventral striatum, which is innervated by dopamine and 
characterized by a relative density of the D3 receptor subtype compared to other brain 
regions. Reuter et al. (2005), using fMRI technology, reported that individuals 
diagnosed with pathological gambling had decreased activation in the right ventral 
striatum relative to matched controls while completing a gambling task. Further, 
striatal activation within the sample of pathological gamblers was negatively 
correlated with gambling severity. On the whole, this reduced activation is similar to 
that found in drug-addicted individuals (see Volkow, Fowler, Wang, & Goldstein, 
2002 for a review). Beyond these similarities in brain activity, however, it is currently 
unknown whether diminished activation in these areas is the result of addiction or 
whether lower levels of striatal activity selectively predispose individuals to engage 
in impulsive behavior such as drug-taking or gambling. 
 When coupled with dopamine agonists, hypoactivation of the striatum is 
strongly correlated with risky decision-making. Recent studies have shown that 
dopamine agonist medications like pramipexole, while enhancing dopaminergic tone 
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in general, may reduce activation along mesolimbic pathways and disrupt processes 
essential to reward-related learning and reward prediction. For instance, fMRI 
measures suggest acute pramipexole blunts responding along the cortical loop 
containing the striatum and other structures (Riba et al., 2008). Moreover, these 
authors reported that this hypoactivation was accompanied by an increased likelihood 
to choose a less conservative option in a lottery-style gambling task when compared 
with choices the same human participants made during placebo sessions. Likewise, 
Pizzagalli et al. (2008) found a single acute dose of pramipexole (0.5 mg) disrupted 
the ability of healthy human volunteers to learn to select a more frequently rewarded 
alternative during a probabilistic differential reinforcement task relative to a control 
group receiving a placebo. However, individuals receiving chronic treatment with 
dopamine agonists such as pramipexole, ropinirole, and cabergoline (average 0.47 
mg/dose pramipexole equivalent) exhibit greater activation of the mesolimbic reward 
system (e.g., ventral striatum, orbitofrontal cortex) relative to their “off-DA” 
performance during a probabilistic monetary task (Abler, Hahlbrock, Unrath, Grön, & 
Kassubek, 2009). Despite this absence of agonist-related reductions in brain 
activation when agonists are taken chronically, Abler et al.’s human participants 
displayed reward prediction signaling contrary to that observed in seminal work by 
Schultz and colleagues with nonhuman primates (Fiorillo, Tobler, & Schultz, 2003; 
Schultz, 1998; Waelti, Dickinson, & Schultz, 2001). Although these findings 
collectively demonstrate the potential for pramipexole and other dopamine agonists to 
impair learning processes in novel tasks, the question of why steady-state preference 
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was affected in the present study remains unanswered. Nonetheless, the studies 
reviewed above suggest a critical role for dopamine and dopamine agonists in reward 
processing. 
In the present study, acute pramipexole increased rats’ preferences for 
gambling-like sources of reinforcement. The results of the aforementioned studies 
suggest two interpretations. First, pramipexole may enhance an organism’s sensitivity 
to the unpredictable scheduling of rewards operating on gambling-like schedules. 
Evidence for this sensitization effect comes from work by Fiorillo et al. (2003). They 
reported that the activity of dopamine neurons in the ventral striatum peaked and 
sustained under conditions of maximum uncertainty (i.e., reward probability = 0.5). If 
pramipexole decreases activation of dopaminergic neurons in regions specific to 
reward valuation and learning, then engagement in unpredictable and impulsive 
courses of action may induce supplementary dopamine transmission. In other words, 
impulsive behavior observed under dopamine agonists may represent compensatory 
efforts on the part of the individual to regulate striatal dopamine concentrations (e.g., 
Riba et al., 2008).  
 Second, pramipexole may desensitize an organism to the effects of aversive 
outcomes, such as the income loss experienced by our rats in sessions in which they 
chose the “higher-priced” variable-ratio alternative. The interpretation that 
pramipexole reduces the psychological effects of aversive outcomes is partially 
supported by the results of a recent study by Bódi et al. (2009). In their study, DA-
agonist medicated and never-medicated young onset PD patients were tested on 
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feedback-based probabilistic classification tasks (e.g., card-sorting) and measures of 
novelty-seeking. In the feedback-based task, participants were asked to assign stimuli 
to one of two classes (A or B) depending upon feedback from previous trials 
involving differential rewards (80 trials) and punishments (80 trials) contingent upon 
correct or incorrect answers, respectively. Across four blocks of 20 trials in the 
reward-learning phase, PD patients receiving dopamine agonists (i.e., pramipexole 
[mean dose: 4.5 mg/day] or ropinirole [mean dose: 5.5 mg/day]) showed optimal 
learning consistent with matched, non-PD controls, whereas performance of never-
medicated PD patients revealed decision-making only slightly higher than chance 
levels. In the punishment-learning phase, the opposite effect occurred: Never-
medicated PD patients learned the task as well as the control group, while the D2/D3 
agonist group demonstrated decision-making consistent with chance. Furthermore, 
after initiating DA agonist therapy, the previously never-medicated group showed 
improvements in reward-related learning and deficits in punishment-related learning 
similar to those observed in the original DA-agonist medicated group. On the whole, 
participants in the Bódi et al. study receiving DA-agonist treatment showed few, if 
any, deficits in reward learning, while at the same time demonstrating a gross 
inability to modulate their choices in the face of punishing consequences. Applied to 
the context of the present study, Bódi et al.’s (2009) findings provide a potential 
explanation of pramipexole-induced increased preference for gambling-like schedules 
of reinforcement in terms of reduced sensitivity to aversive outcomes in the form of 
global reductions in food income. Likely also is the possibility that pramipexole 
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sensitizes an organism to dopaminergic increases resulting from unpredictable reward 
scheduling. While these interpretations are by no means exclusive, further research 
into the effects of pramipexole on reward- and punishment-learning is necessary to 
elaborate their contributions to the present findings. 
 A few limitations of this research deserve comment. First, the function of the 
programmed response budget remains unclear. For example, whether the rats’ 
behavior was sensitive to the molar consequences of income lost, and further, whether 
these losses were perceived as being contingent upon responses allocated to the more 
costly VR alternative is difficult to distinguish. Also, because the response budget 
was derived from the FR value in order to hold maximum reinforcement obtained 
constant across low- and high-gambling baselines, even a modest number of VR 
choices in the low-gambling baseline subtracted disproportionately more from the 
relatively smaller budgets programmed in this condition (e.g., 363 for FR-3). 
Therefore, if the rats were indeed sensitive to these contingencies, then the lower 
response budgets in the low-gambling baseline may have actually resulted in lower 
VR choice in drug sessions than would have otherwise been observed. 
To address this hypothesis, the present study has been systematically 
replicated with the exception of the response budget in seven experimentally naïve 
subjects. The results of the present work were partially reproduced: The same acute 
pramipexole doses increased VR choice in a manner similar to that seen here, 
although the magnitude of these increases at lower doses (e.g., 0.03 & 0.1 mg/kg) was 
substantially reduced (data not shown here). Statistical tests (ANOVA) confirmed VR 
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choice did not differ significantly between the two studies (p = .08), although the dose 
x experiment interaction did trend toward significance (p = .058), likely due to the 
comparatively smaller effects of lower pramipexole doses in the follow-up study. 
Thus, the response budget may not constitute an important variable in our 
conceptualization of human gambling and in determining pramipexole’s capacity to 
induce impulsive behavior. 
 A second limitation is that we did not use Parkinsonian rats. An argument 
could be made that because individuals diagnosed with PD already exhibit common 
neurological markers of addiction (i.e., reduced striatal activity), their predisposition 
to behave impulsively is amplified by dopamine agonist medications, and this 
interaction does not occur in healthy subjects with intact brain function. Future 
research should investigate the effects of such dopamine agonists in Parkinsonian 
animal models. Given these questions, it is clear that the procedures used in the 
present research require ongoing improvement.  
 Despite these limitations, the present study detected measurable increases in 
gambling-like behavior when pramipexole was acutely administered. Whether these 
effects are explicable in terms of deficient reward processing, hypersensitivity to 
unpredictable rewards, or marked insensitivity to aversive outcomes (or all of these 
interpretations simultaneously) is unknown. The findings and procedures 
incorporated herein call for further explication and refinement. We are confident, 
however, that the relation between impulsive behavior in the form of pathological 
gambling and pramipexole, as well as other D2/D3 dopamine agonists with similar 
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affinities, will comprise an increasingly relevant line of inquiry as it pertains to 
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Table 1. Mean percent VR choice; median center, FR, and VR latencies; and mean 
conditional probability of same-lever choice during forced-free transitions in control, 

































Black 4 3/363 Control 8.73 (0.66) 9.68 1.23 0.86  
  Saline 8.53 (2.60) 10.60 1.17 0.90 0.58 (0.07) 
  0.03 30.88 (3.18) 11.75 1.44 1.04 0.50 (0.12) 
  0.1 33.95 (9.65) 19.43 1.59 0.96 0.50 (0.12) 
  0.18 16.83 (2.13) 19.96 1.50 1.14 0.50 (0.12) 
  0.3 19.88 (3.06) 25.01 1.67 1.29 0.42 (0.11) 
Blue 2 5/605 Control 7.50 (0.64) 6.00 1.09 0.89  
  Saline 7.60 (2.91) 8.06 1.13 0.91 0.58 (0.07) 
  0.03 11.58 (7.30) 7.20 1.05 0.89 0.58 (0.07) 
  0.1 24.70 (10.08) 13.06 1.03 0.95 0.42 (0.07) 
  0.18 22.22 (12.70) 15.64 1.15 1.26 0.56 (0.05) 
  0.3 22.35 (11.13) 17.09 1.20 1.29 0.56 (0.05) 
Blue 3 5/605 Control 8.24 (0.65) 5.15 1.11 0.73  
  Saline 7.10 (3.33) 5.58 0.97 0.77 0.50 (0.00) 
  0.03 36.07 (7.11) 7.65 1.08 0.77 0.58 (0.07) 
  0.1 14.43 (2.06) 14.47 1.25 0.77 0.58 (0.07) 
  0.18 35.76 (3.38) 13.06 1.15 0.78 0.67 (0.07) 
  0.3 51.63 (16.82) 14.70 1.84 0.84 0.75 (0.12) 
Blue 4 5/605 Control 1.57 (0.19) 9.91 1.20 1.27  
  Saline 0.00 (0.00) 9.61 1.16 1.42 0.50 (0.00) 
  0.03 2.51 (0.73) 20.21 1.34 1.39 0.42 (0.07) 
  0.1 6.54 (4.19) 25.69 1.22 1.56 0.50 (0.00) 
  0.18 11.59 (3.46) 25.85 1.36 1.55 0.33 (0.07) 
  0.3 15.00 (3.54) 23.78 1.35 1.59 0.50 (0.00) 
Red 1 3/363 Control 2.27 (0.41) 10.25 1.74 1.84  
  Saline 0.97 (0.06) 12.95 1.79 1.90 0.58 (0.07) 
  0.03 13.25 (7.86) 18.26 2.33 2.55 0.50 (0.12) 
  0.1 12.75 (3.43) 25.82 2.12 2.73 0.25 (0.12) 
  0.18 7.56 (3.32) 16.28 1.88 2.31 0.47 (0.10) 
  0.3 16.09 (5.28) 19.47 2.41 2.60 0.36 (0.06) 
Red 2 2/242 Control 14.11 (1.76) 7.03 1.17 0.78  
  Saline 4.27 (1.76) 9.22 1.18 0.76 0.58 (0.07) 
  0.03 32.50 (3.12) 8.72 1.26 0.81 0.83 (0.07) 
  0.1 21.21 (3.86) 14.75 1.27 0.90 0.50 (0.00) 
  0.18 13.93 (4.54) 17.65 1.28 0.90 0.42 (0.14) 
  0.3 23.92 (10.66) 18.36 1.12 0.91 0.33 (0.07) 
Red 3 5/605 Control 1.59 (0.21) 8.68 1.04 0.78  
  Saline 0.87 (0.71 ) 8.55 0.96 0.77 0.50 (0.00) 
  0.03 5.39 (1.67) 13.72 1.18 0.89 0.33 (0.07) 
  0.1 16.39 (6.18) 14.60 1.47 0.86 0.42 (0.18) 
  0.18 11.38 (1.87) 13.75 1.20 0.90 0.19 (0.08) 
  0.3 28.33 (9.53) 26.20 1.75 0.96 0.50 (0.24) 
Group  Control 6.29 (1.65) 8.68 1.17 0.86  
  Saline 4.19 (1.26) 9.22 1.16 0.90 0.55 (0.02) 
  0.03 18.88 (4.87) 11.75 1.26 0.89 0.54 (0.06) 
  0.1 18.57 (3.13) 14.75 1.27 0.95 0.45 (0.04) 
  0.18 17.04 (3.32) 16.28 1.28 1.14 0.45 (0.05) 
  0.3 25.32 (4.36) 19.47 1.67 1.29 0.49 (0.05)  
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Table 2. Mean percent VR choice; median center, FR, and VR latencies; and mean 
conditional probability of same-lever choice during free-forced transitions in control, 

































Black 4 40/4840 Control 98.73 (0.14) 23.57 1.20 0.77  
  Saline 98.12 (0.77) 24.24 1.15 0.75 0.50 (0.00) 
  0.03 99.06 (0.77) 36.10 1.79 0.91 0.50 (0.00) 
  0.1 94.26 (2.41) 36.10 1.31 0.96 0.47 (0.10) 
  0.18 88.00 (4.99) 37.02 2.62 1.21 0.33 (0.14) 
  0.3 94.44 (2.40) 48.62 5.37 1.08 0.59 (0.05) 
Blue 2 40/4840 Control 99.41 (0.13) 11.63 1.61 0.83  
  Saline 99.29 (0.58) 10.38 1.50 0.81 0.50 (0.00) 
  0.03 99.66 (0.27) 18.80 2.41 0.92 0.42 (0.07) 
  0.1 100.00 (0.00) 18.55 2.69 1.11 0.50 (0.00) 
  0.18 97.09 (1.19) 14.86 4.32 0.99 0.50 (0.00) 
  0.3 89.10 (2.86) 17.79 2.78 1.03 0.44 (0.05) 
Blue 3 40/4840 Control 97.14 (0.42) 11.36 1.01 0.72  
  Saline 96.58 (0.61) 10.95 1.01 0.71 0.83 (0.07) 
  0.03 98.44 (0.80) 18.57 1.70 0.78 0.67 (0.07) 
  0.1 100.00 (0.00) 21.89 2.47 0.81 0.50 (0.00) 
  0.18 91.11 (2.84) 17.78 2.48 0.81 0.50 (0.00) 
  0.3 100.00 (0.00) 21.53 3.85 0.91 0.39 (0.05) 
Blue 4 40/4840 Control 97.18 (0.57) 8.82 1.17 1.09  
  Saline 92.58 (2.74) 8.05 1.14 1.09 0.67 (0.07) 
  0.03 96.06 (2.44) 12.40 1.40 1.12 0.50 (0.00) 
  0.1 92.14 (5.18) 22.28 1.30 1.05 0.25 (0.12) 
  0.18 95.73 (1.18) 20.25 1.49 1.14 0.50 (0.00) 
  0.3 93.33 (5.44) 27.44 1.82 1.17 0.67 (0.00) 
Red 1 40/4840 Control 98.81 (0.12) 11.26 1.52 1.34  
  Saline 99.69 (0.25) 10.84 1.37 1.34 0.50 (0.00) 
  0.03 93.36 (3.06) 21.75 2.33 1.84 0.42 (0.07) 
  0.1 93.57 (2.19) 24.71 2.40 1.95 0.42 (0.07) 
  0.18 97.31 (2.19) 20.49 2.10 1.82 0.42 (0.07) 
  0.3 92.15 (2.62) 19.50 2.41 1.89 0.42 (0.07) 
Red 2 40/4840 Control 99.46 (0.16) 7.37 1.86 0.78  
  Saline 99.67 (0.27) 8.06 1.35 0.73 0.58 (0.07) 
  0.03 98.95 (0.86) 11.63 5.05 0.85 0.50 (0.00) 
  0.1 99.63 (0.30) 11.50 4.71 0.85 0.58 (0.07) 
  0.18 99.12 (0.72) 13.82 2.85 0.85 0.50 (0.00) 
  0.3 100.00 (0.00) 15.49 2.96 0.90 0.50 (0.00) 
Red 3 40/4840 Control 99.66 (0.09) 9.18 1.35 0.73  
  Saline 99.56 (0.36) 9.73 1.34 0.71 0.58 (0.07) 
  0.03 100.00 (0.00) 12.18 2.97 0.85 0.50 (0.00) 
  0.1 100.00 (0.00) 15.64 4.31 0.90 0.50 (0.00) 
  0.18 100.00 (0.00) 17.26 3.58 0.83 0.44 (0.05) 
  0.3 100.00 (0.00) 17.64 2.38 0.85 0.33 (0.00) 
Group  Control 98.63 (0.37) 11.26 1.35 0.78  
  Saline 97.93 (0.92) 10.38 1.34 0.75 0.60 (0.04) 
  0.03 97.93 (0.84) 18.57 2.33 0.91 0.50 (0.03) 
  0.1 97.09 (1.25) 21.89 2.47 0.96 0.46 (0.04) 
  0.18 95.48 (1.53) 17.78 2.62 0.99 0.46 (0.02) 
  0.3 95.57 (1.56) 19.50 2.78 1.03 0.48 (0.04)  
